BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 36642250)

  • 1. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
    Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
    J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.
    Shree D; Patra CN; Sahoo BM
    Pharm Nanotechnol; 2024; 12(3):229-250. PubMed ID: 37587812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics.
    Datta D; Priyanka Bandi S; Colaco V; Dhas N; Siva Reddy DV; Vora LK
    Int J Pharm; 2024 Jun; 658():124192. PubMed ID: 38703931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
    Lakhani P; Patil A; Majumdar S
    Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of lipid nanoparticles to ocular drug delivery.
    Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology in ocular drug delivery.
    Sahoo SK; Dilnawaz F; Krishnakumar S
    Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Recent Advances in Nano-Based Ocular Drug Delivery.
    Liu LC; Chen YH; Lu DW
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prominence of the dosage form design to treat ocular diseases.
    Campos PM; Petrilli R; Lopez RFV
    Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Topical Ocular Drug Delivery.
    Yellepeddi VK; Palakurthi S
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent perspectives in ocular drug delivery.
    Gaudana R; Jwala J; Boddu SH; Mitra AK
    Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies for anterior segment ocular drug delivery.
    Cholkar K; Patel SP; Vadlapudi AD; Mitra AK
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):106-23. PubMed ID: 23215539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
    Srinivasarao DA; Lohiya G; Katti DS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular Drug Delivery: Present Innovations and Future Challenges.
    Gote V; Sikder S; Sicotte J; Pal D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic nano-bioconjugates: critical challenges and technological advances.
    Sanap SN; Bisen AC; Agrawal S; Kedar A; Bhatta RS
    Ther Deliv; 2023 Jul; 14(7):419-441. PubMed ID: 37535389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.
    Bravo-Osuna I; Andrés-Guerrero V; Pastoriza Abal P; Molina-Martínez IT; Herrero-Vanrell R
    Drug Deliv Transl Res; 2016 Dec; 6(6):686-707. PubMed ID: 27766598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.
    Vaneev A; Tikhomirova V; Chesnokova N; Popova E; Beznos O; Kost O; Klyachko N
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology-based formulations to amplify intraocular bioavailability.
    Kagkelaris K; Panayiotakopoulos G; Georgakopoulos CD
    Ther Adv Ophthalmol; 2022; 14():25158414221112356. PubMed ID: 35873277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.